AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19434697 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler technique
Number of subjects: 70
Study 19434697 — intervention group
Group type: COMPARATOR
Intervention: Stapler combined with seromuscular patch
Number of subjects: 70
Study 19434697 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 70
Study 16479752 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded tapered implants with single provisional crowns at surgery and definitive crowns 8 weeks later
Number of subjects: 0
Study 16479752 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-stage implants
Number of subjects: 0
Study 12547850 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 17
Study 12547850 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 17
Study 10861333 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (60 ± 6.7% fat)
Number of subjects: 14
Study 10861333 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (63 ± 3.2% carbohydrate)
Number of subjects: 14
Study 10861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (4190 kJ, 70% VO2max)
Number of subjects: 14
Study 8618160 — intervention group
Group type: EXPERIMENTAL
Intervention: Total meniscectomy
Number of subjects: 33
Study 8618160 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 33
Study 8618160 — intervention group
Group type: COMPARATOR
Intervention: Healthy contralateral knees
Number of subjects: 33
Study 1526265 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram of alphacalcidol daily for 4 months
Number of subjects: 39
Study 1526265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3903813 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-phenylalanine
Number of subjects: 19
Study 3903813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3903813 — intervention group
Group type: EXPERIMENTAL
Intervention: Open drug (DL-phenylalanine)
Number of subjects: 19
Study 3903813 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine
Number of subjects: 19
Study 30576416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage cues
Number of subjects: 17
Study 30576416 — intervention group
Group type: COMPARATOR
Intervention: Control (water) cues
Number of subjects: 17
Study 30576416 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning performance
Number of subjects: 17
Study 30576416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic liver disease
Number of subjects: 17
Study 29132842 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3% glucose/saline (51mEq/L sodium and 33g/L glucose)
Number of subjects: 130
Study 29132842 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose/saline (154mEq/L sodium and 50g/L glucose)
Number of subjects: 130
Study 26242890 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management and health promotion program
Number of subjects: 61
Study 26242890 — intervention group
Group type: COMPARATOR
Intervention: Observational control program
Number of subjects: 61
Study 24868587 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment (experimental group)
Number of subjects: 153
Study 24868587 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological therapy (control group)
Number of subjects: 153
Study 22466322 — intervention group
Group type: EXPERIMENTAL
Intervention: Q/LAIV
Number of subjects: 0
Study 22466322 — intervention group
Group type: COMPARATOR
Intervention: T/LAIV
Number of subjects: 0
Study 20723636 — intervention group
Group type: COMPARATOR
Intervention: QRS score 0 to 3 (<=10% myocardium)
Number of subjects: 4113
Study 20723636 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score 4 to 7 (10% to 21% myocardium)
Number of subjects: 4113
Study 20723636 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score >=8 (>21% myocardium)
Number of subjects: 4113
Study 18540854 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16200820 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via Clickhaler
Number of subjects: 28
Study 16200820 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via Aerolizer
Number of subjects: 28
Study 16200820 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via pMDI
Number of subjects: 28
Study 12358339 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast added to ICS for 3 weeks (group M)
Number of subjects: 35
Study 12358339 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) only (group C)
Number of subjects: 35
Study 12358339 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast withdrawal after 2 weeks (group M)
Number of subjects: 35
Study 10364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 30
Study 10364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 30
Study 10364998 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 30
Study 7863760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefuroxime (3 g infused in 15-25 min in preliminary study, 3 g infused in 15 min in main study)
Number of subjects: 40
Study 1778193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice a day
Number of subjects: 64
Study 1778193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg daily
Number of subjects: 64
Study 1778193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6785801 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 52
Study 31529663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of autologous bone marrow mononuclear cells (MNCs) at a target dose of 10 million cells per kilogram, administered within 24-72 hours of stroke onset.
Number of subjects: 25
Study 31529663 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of autologous bone marrow mononuclear cells (MNCs)
Number of subjects: 25
Study 27554783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stems
Number of subjects: 23
Study 27554783 — intervention group
Group type: COMPARATOR
Intervention: Hybrid stems
Number of subjects: 23
Study 26373634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Number of subjects: 120
Study 26373634 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 120
Study 23416800 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol with magnesium sulphate
Number of subjects: 120
Study 23416800 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol with normal saline
Number of subjects: 120
Study 21242584 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (IMQ) once daily, 5 days/week for 6 weeks
Number of subjects: 27
Study 21242584 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 27
Study 19568709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola-Gingko Capsule (RGC), 270 mg herbal extracts, 4 capsules per day for 7 weeks
Number of subjects: 70
Study 19568709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17353578 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular red wine (250 ml)
Number of subjects: 20
Study 17353578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (250 ml)
Number of subjects: 20
Study 17353578 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking (one cigarette)
Number of subjects: 20
Study 14753131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified CHOP for patients ≤ 60 years; CHOP with growth factors for patients > 60 years (clinical trial group)
Number of subjects: 59
Study 14753131 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy in routine clinical practice (RCP)
Number of subjects: 59
Study 11491635 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (28 capsules of 500 mg taken every 6 hours for 7 days)
Number of subjects: 41
Study 11491635 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 41
Study 9306523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity procedure
Number of subjects: 11
Study 9306523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amplitude procedure
Number of subjects: 11
Study 9306523 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial posture variation
Number of subjects: 11
Study 9306523 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 11
Study 9306523 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 11
Study 8190329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal peritoneal dialysis (TPD)
Number of subjects: 8
Study 8190329 — intervention group
Group type: COMPARATOR
Intervention: Continuous cyclic peritoneal dialysis (CCPD)
Number of subjects: 8
Study 3286680 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous follicle aspiration
Number of subjects: 47
Study 3286680 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal puncture
Number of subjects: 47
Study 3286680 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous approach
Number of subjects: 47
Study 3286680 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal technique
Number of subjects: 47
Study 29909091 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5/FU2 + irinotecan
Number of subjects: 2982
Study 29909091 — intervention group
Group type: COMPARATOR
Intervention: LV5/FU2
Number of subjects: 2982
Study 26025780 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (15 Hz)
Number of subjects: 32
Study 26025780 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study 23833854 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 80
Study 23833854 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine
Number of subjects: 80
Study 23833854 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lignocaine
Number of subjects: 80
Study 23833854 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% hyperbaric lignocaine
Number of subjects: 80
Study 20629481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of Labor (TOL)
Number of subjects: 203
Study 20629481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Birth After Cesarean (VBAC)
Number of subjects: 203
Study 20629481 — intervention group
Group type: COMPARATOR
Intervention: Elective Repeat Cesarean Delivery (ERCD)
Number of subjects: 203
Study 20629481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of Labor (TOL) with previa
Number of subjects: 203
Study 18756940 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 228
Study 18756940 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 228
Study 16809258 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (EDA) with ropivacaine + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Number of subjects: 40
Study 16809258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone hydrochloride (2 x 10 mg tablet) + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Number of subjects: 40
Study 14516039 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tricortical graft
Number of subjects: 42
Study 14516039 — intervention group
Group type: COMPARATOR
Intervention: Cage
Number of subjects: 42
Study 10566625 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/day for 3 months)
Number of subjects: 60
Study 10566625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10160231 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HRA feedback
Number of subjects: 0
Study 10160231 — intervention group
Group type: COMPARATOR
Intervention: Typical HRA feedback
Number of subjects: 0
Study 10160231 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 0
Study 1870549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 0
Study 1870549 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0
Study 6688799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg per os daily for 6 months
Number of subjects: 60
Study 6688799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg per os daily for 6 months
Number of subjects: 60
Study 6688799 — intervention group
Group type: COMPARATOR
Intervention: Topical antacids as needed for 6 months
Number of subjects: 60
Study 3926806 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg, iv every 3 hours for 9-12 days)
Number of subjects: 7
Study 29383606 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo carmine mixed solution
Number of subjects: 212
Study 29383606 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 212
Study 27378823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg bid 24 h prior to ascent
Number of subjects: 41
Study 27378823 — intervention group
Group type: COMPARATOR
Intervention: High altitude exposure
Number of subjects: 41
Study 27378823 — intervention group
Group type: COMPARATOR
Intervention: Baseline suPAR plasma concentration
Number of subjects: 41
Study 24919538 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 82
Study 22778119 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive preventive health record (IPHR)
Number of subjects: 4500
Study 22778119 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4500
Study 22778119 — intervention group
Group type: EXPERIMENTAL
Intervention: IPHR users
Number of subjects: 4500
Study 20193645 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 to 50 mg
Number of subjects: 313
Study 20193645 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 to 100 mg
Number of subjects: 313
Study 18923706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (200 mg for children, 400 mg for adults)
Number of subjects: 123
Study 18923706 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (200 mg for children, 400 mg for adults)
Number of subjects: 123
Study 16168630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 12
Study 16168630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.00 mg
Number of subjects: 12
Study 16168630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12689685 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 0
Study 12689685 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 0
Study 10685273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Care Manual of the Perinatal Education Programme
Number of subjects: 93
Study 10685273 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 8712440 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education and individualized feedback on anesthesiologist performance
Number of subjects: 0
Study 8712440 — intervention group
Group type: COMPARATOR
Intervention: Control hospital with usual practice
Number of subjects: 0
Study 1754670 — intervention group
Group type: EXPERIMENTAL
Intervention: Food elimination diet (avoiding cows' milk, eggs, tomatoes, and possibly colours and preservatives)
Number of subjects: 91
Study 1754670 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk and tomato food challenges
Number of subjects: 91
Study 1754670 — intervention group
Group type: COMPARATOR
Intervention: Egg food challenge
Number of subjects: 91
Study 1754670 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of food avoidance
Number of subjects: 91
Study 1754670 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical history
Number of subjects: 91
Study 6131526 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (15 mg)
Number of subjects: 13
Study 6131526 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 13
Study 6131526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31992133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based warm-up programme ('VolleyVeilig')
Number of subjects: 672
Study 31992133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 672
Study 31033140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioexchange
Number of subjects: 64
Study 31033140 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 64
Study 29165021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 327
Study 29165021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 26011606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat condition (task described as very painful, high pain expressions depicted)
Number of subjects: 48
Study 26011606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threat condition (standard CPT instructions provided, low pain expressions depicted) with informed ceiling (maximum immersion time provided)
Number of subjects: 48
Study 26011606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threat condition (standard CPT instructions provided, low pain expressions depicted) with uninformed ceiling (information about maximum immersion time omitted)
Number of subjects: 48
Study 23932198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular tenoxicam injection (20 mg)
Number of subjects: 16
Study 23932198 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis plus sodium hyaluronate injection
Number of subjects: 16
Study 22341892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine wound infusion
Number of subjects: 66
Study 22341892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with saline wound infusion
Number of subjects: 66
Study 22341892 — intervention group
Group type: COMPARATOR
Intervention: Saline wound infusion
Number of subjects: 66
Study 20651413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise and education (AE; aquatic exercise twice a week with once-a-week group education)
Number of subjects: 79
Study 20651413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise and education (AE)
Number of subjects: 79
Study 20651413 — intervention group
Group type: COMPARATOR
Intervention: Aquatics only (A; 2 week aquatic exercise)
Number of subjects: 79
Study 20651413 — intervention group
Group type: COMPARATOR
Intervention: Control (C; usual activity)
Number of subjects: 79
Study 18039987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing feedback regarding calculated coronary risk
Number of subjects: 3053
Study 18039987 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3053
Study 16104026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral bioanalytical method
Number of subjects: 0
Study 16104026 — intervention group
Group type: COMPARATOR
Intervention: Nonchiral bioanalytical method
Number of subjects: 0
Study 11231747 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/d of vitamin E
Number of subjects: 30
Study 11231747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin E
Number of subjects: 30
Study 11231747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 1329
Study 11284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1329
Study 11284462 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 25 mg
Number of subjects: 1329
Study 11284462 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 1329
Study 11284462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1329
Study 7821076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail osteosynthesis
Number of subjects: 330
Study 7821076 — intervention group
Group type: EXPERIMENTAL
Intervention: New gliding nail (GN)
Number of subjects: 330
Study 3392410 — intervention group
Group type: COMPARATOR
Intervention: First period (1973-1981)
Number of subjects: 295
Study 3392410 — intervention group
Group type: EXPERIMENTAL
Intervention: Second period (1982-1987)
Number of subjects: 295
Study 4923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 10
Study 4923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 4923642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31752094 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >24 months
Number of subjects: 307
Study 31752094 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding to six months with breastfeeding <24 months
Number of subjects: 307
Study 31752094 — intervention group
Group type: COMPARATOR
Intervention: Never breastfed
Number of subjects: 307
Study 28758128 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face training during paediatric practice
Number of subjects: 50
Study 28758128 — intervention group
Group type: EXPERIMENTAL
Intervention: Training videos supervised by sanitary personnel
Number of subjects: 50
Study 26096070 — intervention group
Group type: EXPERIMENTAL
Intervention: MB‐TKA inserts
Number of subjects: 146
Study 26096070 — intervention group
Group type: COMPARATOR
Intervention: FB‐TKA inserts
Number of subjects: 146
Study 26096070 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometry, temporal gait parameters and QoL
Number of subjects: 146
Study 24832767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavotricuspid isthmus ablation with concomitant pulmonary vein isolation
Number of subjects: 50
Study 24832767 — intervention group
Group type: COMPARATOR
Intervention: Cavotricuspid isthmus ablation only
Number of subjects: 50